Lakeshore Biopharma CO., LTD. (LSBWF) SEC Filings — 2024
34 SEC filings for Lakeshore Biopharma CO., LTD. (LSBWF) in 2024.
Filings
- LakeShore Biopharma Files 6-K Report — 6-K · Dec 19, 2024
- LakeShore Biopharma Updates on Former Chairman's Criminal Probe — 6-K · Dec 12, 2024
- LakeShore Biopharma Changes Auditor to Grant Thornton — 6-K · Nov 12, 2024
- LakeShore Biopharma Files 6-K Report — 6-K · Nov 7, 2024
- LakeShore Biopharma Announces Marketing Head Resignation — 6-K · Nov 1, 2024
- LakeShore Biopharma Files 6-K Report — 6-K · Oct 29, 2024
- LakeShore Biopharma Files 6-K Report — 6-K · Oct 25, 2024
- LakeShore Biopharma Files 6-K with FY2025 Half Year Results — 6-K · Oct 8, 2024
- LakeShore Biopharma Holds Shareholder Meeting — 6-K · Sep 27, 2024
- LakeShore Biopharma Calls Extraordinary General Meeting — 6-K · Sep 10, 2024
- LakeShore Biopharma Files 6-K Report — 6-K · Sep 4, 2024
- LakeShore Biopharma Files 2024 Annual Report — 20-F · Aug 15, 2024
- LakeShore Biopharma Announces Extraordinary General Meeting — 6-K · Jul 5, 2024
- LakeShore Biopharma Director Resigns — 6-K · Jun 18, 2024
- LakeShore Biopharma Directors Depart — 6-K · Jun 10, 2024
- YS Biopharma Changes Name to LakeShore Biopharma — 6-K · May 24, 2024
- YS Biopharma Holds EGM, Approves All Resolutions — 6-K · May 21, 2024
- YS Biopharma to Hold Extraordinary General Meeting — 6-K · May 7, 2024
- YS Biopharma Gets 180-Day Nasdaq Bid Price Extension — 6-K · Apr 29, 2024
- YS Biopharma Files 6-K with FY2024 Nine-Month Financials — 6-K · Apr 19, 2024
- YS Biopharma Gets Phase I License for Hep B Vaccine — 6-K · Apr 18, 2024
- YS Biopharma's PIKA Rabies Vaccine Shows Positive Phase 3 Results — 6-K · Apr 9, 2024
- YS Biopharma Repays $40M Loan — 6-K · Apr 3, 2024
- YS Biopharma Announces Leadership Changes — 6-K · Mar 5, 2024
- YS Biopharma Updates Share Ownership, Confirms Foreign Issuer Status — 6-K · Feb 23, 2024
- YS Biopharma Holds EGM, Discloses Results in 6-K Filing — 6-K · Feb 22, 2024
- YS Biopharma Holds EGM, Addresses False Statements — 6-K · Feb 20, 2024
- Ys Biopharma CO., LTD. SC 13G/A Filing — SC 13G/A · Feb 16, 2024
- Ys Biopharma CO., LTD. SC 13G Filing — SC 13G · Feb 15, 2024
- YS Biopharma Reports Director Removal in February 6-K Filing — 6-K · Feb 14, 2024
- YS Biopharma Secures $40M Private Placement, Issues 95.2M Shares — 6-K · Feb 9, 2024
- YS Biopharma Subsidiary Notified of Loan Default by R-Bridge — 6-K · Jan 26, 2024
- YS Biopharma Reports Unaudited H1 FY24 Financial Results — 6-K · Jan 22, 2024
- YS Biopharma Appoints Rui Yu as Audit Committee Chairperson — 6-K · Jan 8, 2024